Human RCTPubMed ID: 2865854·1985

Thymosin alpha-1 pharmacokinetics and tissue distribution in humans

Schulof RS, Threshold J, Reuben JM, et al.

Journal of Clinical Pharmacology, 1985 · n = 12

Key finding

Thymosin alpha-1 t1/2 ~40 minutes (IV); peak serum concentration 2-4 hours post-SC; thymus tissue accumulation confirmed.

Summary

Pharmacokinetic study measuring thymosin alpha-1 serum levels, half-life, and tissue accumulation following parenteral administration.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

Thymosin Alpha-1L4

A naturally occurring thymic peptide approved internationally for immune modulation, with extensive clinical data in hepatitis and cancer immunotherapy.

More research on Thymosin Alpha-1

COVID-19 immunotherapy: thymosin alpha-1 efficacy in severe disease

Cytokine · 2021 · Human RCT

Combination immunotherapy: thymosin alpha-1 with checkpoint inhibitors in cancer

Journal for ImmunoTherapy of Cancer · 2020 · Human Pilot

Thymalfasin: clinical pharmacology and antiviral applications

BioDrugs · 2010 · Review

Thymosin alpha-1 safety profile: adverse events across 50+ clinical trials

Current Aging Science · 2010 · Review

Thymosin alpha-1 and thymic regeneration in aging

Nature Immunology · 2009 · Animal Study